A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
Sven De Vos
Research Funding - Gilead Sciences
Laurie Helen Sehn
Research Funding - Gilead Sciences
Stephen P. Mulligan
Research Funding - Gilead Sciences
Martin H. Dreyling
Research Funding - Gilead Sciences
Mathias J. Rummel
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Myron Stefan Czuczman
Research Funding - Gilead Sciences